BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Shield Therapeutics 

Abbey House
Wellington Way
Weybridge       United Kingdom
Phone: +44 (0)1932-268436 Fax: +44 (0)870 458-6523


SEARCH JOBS





Segment
Pharmaceuticals





 Company News
Shield Therapeutics Announces Acceptance Of ST10 Abstract For Presentation At ECCO Congress 2014 2/4/2014 12:45:28 PM
Shield Therapeutics' ST10 Delivers Robust Results Meeting Both Primary And Secondary Endpoints In The Pivotal AEGIS Phase 3 Program For The Treatment Of Iron Deficiency Anemia In Inflammatory Bowel Disease 1/7/2014 6:54:16 AM
Shield Therapeutics Release: FDA Grants Approval Of IND To Commence A Phase 3 Pivotal Study For ST10 For The Treatment Of Iron Deficiency Anemia In Chronic Kidney Disease 12/16/2013 8:44:15 AM
Shield Therapeutics Files Investigational New Drug Application For ST10 For The Treatment Of Iron Deficiency In Chronic Kidney Disease 11/12/2013 9:03:14 AM
Shield Therapeutics to Attend Biotechnology Industry Organization (BIO)-Europe® 2013 10/23/2013 6:43:54 AM
Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency 6/24/2013 11:19:11 AM
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 10/12/2011 5:55:21 AM
Shield Therapeutics Raises EUR8.2 Million From Inventages Venture Capital Via Series A Institutional Round 6/1/2011 6:47:48 AM
Shield Therapeutics Appoints Richard Jones as Chief Financial Officer 5/16/2011 10:54:48 AM
Shield Therapeutics to Present at the Biotech Showcase 2011 1/7/2011 10:43:54 AM